•  John M. Pruneau, Lindsay Trammell, Rachael R. Jetson | Discovery Sciences, Valo Health, 75 Hayden Ave Lexington, Massachusetts

Poster: Automated Discovery: Streamlining Processes to Enable Rapid Drug Discovery via DEL and IVP


Select­ing lead mol­e­cules of the high­est pos­si­ble qual­i­ty is cru­cial for the suc­cess of any drug dis­cov­ery cam­paign. It stands to rea­son that increas­ing the size and diver­si­ty of screen­ing decks increas­es the prob­a­bil­i­ty of find­ing hits that progress to bet­ter lead mol­e­cules. Over the past cou­ple decades, auto­mat­ed tech­niques have been wide­ly adopt­ed for liq­uid han­dling, plate pro­cess­ing, and analy­sis dur­ing high through­put screen­ing (HTS). This has allowed screen­ing of greater num­bers of com­pounds while simul­ta­ne­ous­ly reduc­ing assay scale and bur­den on researchers. Sim­i­lar­ly, in recent years DNA encod­ed library (DEL) tech­nol­o­gy has been rapid­ly grow­ing across drug dis­cov­ery. Tra­di­tion­al­ly DELs were con­struct­ed man­u­al­ly using a split and pool com­bi­na­to­r­i­al approach, but as library sizes and the num­ber of tar­gets grow, the impor­tance of automat­ing syn­the­sis and selec­tion has become appar­ent. Here, we describe the var­i­ous automa­tion instru­ments used in our dis­cov­ery work­flow to sup­port both the in vit­ro phar­ma­col­o­gy (IVP) and DEL groups at Valo, and how these are advanc­ing our capabilities.